Indication: Gastrointestinal Cancer
A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Trac
Sub-indication: Gastrointestinal Cancer
Drug Study
Principal Investigator: Michael Driscoll, M.D.Norton Cancer Institute
Sponsor: NuCana, plc
Email for more information: GI-NCIResearch@nortonhealthcare.org
